Q-omics provides the consensus-scored FEM1AP4 profile across patient tissues and cancer cell-line models. FEM1AP4 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, FEM1AP4 is differentially expressed in 6, with the highest sampling consensus in BRCA. Additionally, FEM1AP4 RNA expression shows 6,280 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, BRCA, and TGCT as cancer lineages where FEM1AP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FEM1AP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FEM1AP4 survival associations across molecular data types. FEM1AP4 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FEM1AP4 RNA expression–survival associations across cancer types. High FEM1AP4 expression shows unfavorable associations in ACC, UVM, LUAD, KICH and LIHC, but favorable associations in LUSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .012). Together, the overview and detailed table identify ACC as the clearest survival context for FEM1AP4 RNA expression.
This table summarizes FEM1AP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for FEM1AP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FEM1AP4 shows lower tumor expression in BRCA, ESCA and KIRP and higher tumor expression in KIRC, BLCA and LUSC. The BRCA box plot shows higher FEM1AP4 RNA expression in normal versus tumor tissue (log2 FC = −0.039, t-test p < 0.001).
This table shows molecular features associated with FEM1AP4 in patient tissues and cancer cell lines. In patient samples, FEM1AP4 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
